DK0387867T3 - Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse - Google Patents

Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse

Info

Publication number
DK0387867T3
DK0387867T3 DK90104875.1T DK90104875T DK0387867T3 DK 0387867 T3 DK0387867 T3 DK 0387867T3 DK 90104875 T DK90104875 T DK 90104875T DK 0387867 T3 DK0387867 T3 DK 0387867T3
Authority
DK
Denmark
Prior art keywords
cycloserine
alanine
cognitive
treat
psychotic disorder
Prior art date
Application number
DK90104875.1T
Other languages
English (en)
Inventor
Alexis A Cordi
Michael R Jans
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0387867T3 publication Critical patent/DK0387867T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK90104875.1T 1989-03-15 1990-03-15 Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse DK0387867T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (1)

Publication Number Publication Date
DK0387867T3 true DK0387867T3 (da) 1993-06-01

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90104875.1T DK0387867T3 (da) 1989-03-15 1990-03-15 Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse

Country Status (17)

Country Link
US (1) US5061721A (da)
EP (1) EP0387867B1 (da)
JP (1) JP2963720B2 (da)
KR (1) KR900013961A (da)
AT (1) ATE88890T1 (da)
AU (1) AU624917B2 (da)
CA (1) CA2010635C (da)
DE (1) DE69001503T2 (da)
DK (1) DK0387867T3 (da)
ES (1) ES2055197T3 (da)
FI (1) FI901289A0 (da)
GR (1) GR3008225T3 (da)
IE (1) IE64130B1 (da)
IL (1) IL93562A (da)
NO (1) NO901198L (da)
NZ (1) NZ232809A (da)
PT (1) PT93424B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (en) * 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP2002513380A (ja) 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
WO1998003541A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
ATE369848T1 (de) 1998-04-14 2007-09-15 Gen Hospital Corp Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2002078615A2 (en) 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
JP4824268B2 (ja) * 2001-05-02 2011-11-30 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 学習および記憶を増強させるためのカルボニックアンヒドラーゼ活性化剤
CA2478808A1 (en) * 2002-03-15 2003-09-25 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
CA2528622C (en) * 2003-05-27 2010-08-03 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7544478B2 (en) * 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
JP2007517049A (ja) 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
SG11201505934XA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
NO901198D0 (no) 1990-03-14
PT93424A (pt) 1990-11-07
JP2963720B2 (ja) 1999-10-18
US5061721A (en) 1991-10-29
IE64130B1 (en) 1995-07-12
IL93562A (en) 1996-01-31
PT93424B (pt) 1996-08-30
CA2010635A1 (en) 1990-09-15
EP0387867A1 (en) 1990-09-19
NZ232809A (en) 1992-05-26
KR900013961A (ko) 1990-10-22
FI901289A0 (fi) 1990-03-15
AU5073490A (en) 1990-09-20
AU624917B2 (en) 1992-06-25
ES2055197T3 (es) 1994-08-16
EP0387867B1 (en) 1993-05-05
DE69001503D1 (de) 1993-06-09
DE69001503T2 (de) 1993-09-09
GR3008225T3 (da) 1993-09-30
CA2010635C (en) 2001-03-06
NO901198L (no) 1990-09-17
IL93562A0 (en) 1990-11-29
IE900921L (en) 1990-09-15
JPH03148221A (ja) 1991-06-25
ATE88890T1 (de) 1993-05-15

Similar Documents

Publication Publication Date Title
DK0387867T3 (da) Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
EP0223257A3 (en) Hair stabilizing composition
DK165191C (da) L-carnitin-producerende mikroorganismer samt fremgangsmaade til fremstilling af l-carnitin under anvendelse af mikroorganismerne
DK472688D0 (da) Anvendelse af bezafibrat til behandling af diabetes
NO832554L (no) Middel for behandling av saar
DK327183D0 (da) Fremgangsmade til udfoerelse af elektromikrobiel reduktion
DE3684745D1 (de) Photopolymerisierbare zusammensetzung mit dizyklopentylacrylat oder methacrylat enthaltenden acrylcopolymeren.
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DK0410430T3 (da) Fremgangsmåde til mikrobiologisk diskontinuerlig fremstilling af L-carnitin
DK207384D0 (da) Anvendelse af difunktionelle acrylsyre-og methacrylsyreestere til fremstilling af haerdelige knogle-cementer
DE3273177D1 (en) Trans-dihyldrolisuride antipsychotic
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
EP0092386A3 (en) Hydantoin therapeutic agents
FR2481702B1 (da)
ATE68175T1 (de) Verfahren zur herstellung von l,l oder d,d oder racemat n6 benzyloxycarbonyl 2,6 diaminopimelinsaeuremonoamid.
DK425886D0 (da) Oejengelsammensaetning og fremgangsmaade til behandling af oejeninfektioner
ATA408383A (de) Anlage zur biologischen sanierung von gewaessern durch zufuhr von sauerstoff